|
31 Jul 2009 |
Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
|
|
31 Jul 2009 |
BioInvent signs Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for the Discovery and Development of Therapeutic Antibodies
|
|
31 Jul 2009 |
Merck KGaA Has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung Cancer
|
|
31 Jul 2009 |
ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer
|
|
30 Jul 2009 |
GLAXOSMITHKLINE AND GENMAB ANNOUNCE TOP-LINE RESULTS FOR OFATUMUMAB IN RHEUMATOID ARTHRITIS
|
|
30 Jul 2009 |
Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
|
|
30 Jul 2009 |
Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface Receptors
|
|
30 Jul 2009 |
Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
|
|
30 Jul 2009 |
ArmaGen engineers IgG-decoy receptor fusion protein
|
|
29 Jul 2009 |
BTG plc: AstraZeneca to progress CytoFab™ into Phase IIb study
|
|
29 Jul 2009 |
European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer
|
|
29 Jul 2009 |
Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)
|
|
28 Jul 2009 |
Active Biotech's Cancer Project ANYARA Featured in Journal of Clinical Oncology
|
|
27 Jul 2009 |
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
|
|
24 Jul 2009 |
RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PHASE II STUDY IN RELAPSED DLBCL
|
|
24 Jul 2009 |
OMT Announces a Breakthrough in the Development of a Novel Human Antibody Platform
|
|
24 Jul 2009 |
MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
|
|
24 Jul 2009 |
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
|
|
24 Jul 2009 |
Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
|
|
24 Jul 2009 |
Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseases
|
|
24 Jul 2009 |
Merck KGaA Considers Appealing CHMP Opinion on Erbitux ATreatment for Non-Small Cell Lung Cancer
|
|
23 Jul 2009 |
First Patient Enrolled in Regeneron and Bayer HealthCare VEGF Trap-Eye Phase 3 Program in Central Retinal Vein Occlusion
|
|
22 Jul 2009 |
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
|
|
20 Jul 2009 |
Nycomed announces FDA filing for Daxas® in COPD
|
|
20 Jul 2009 |
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
|
